BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hu HJ, Mao H, Tan YQ, Shrestha A, Ma WJ, Yang Q, Wang JK, Cheng NS, Li FY. Clinical value of preoperative serum CA 19-9 and CA 125 levels in predicting the resectability of hilar cholangiocarcinoma. Springerplus. 2016;5:551. [PMID: 27190750 DOI: 10.1186/s40064-016-2181-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Brown ZJ, Patwardhan S, Bean J, Pawlik TM. Molecular diagnostics and biomarkers in cholangiocarcinoma. Surg Oncol 2022;44:101851. [PMID: 36126350 DOI: 10.1016/j.suronc.2022.101851] [Reference Citation Analysis]
2 Ruzzenente A, Alaimo L, Caputo M, Conci S, Campagnaro T, De Bellis M, Bagante F, Pedrazzani C, Guglielmi A. Infectious complications after surgery for perihilar cholangiocarcinoma: A single Western center experience. Surgery 2022:S0039-6060(22)00292-6. [PMID: 35618490 DOI: 10.1016/j.surg.2022.04.028] [Reference Citation Analysis]
3 Song J, Lei X, Lin H, Dai H, Liu X, Jiang Y, Hu F, Li Y, Fan H, Zhang L, Chen Z, Zhang C. Predictive model for the intraoperative unresectability of hilar cholangiocarcinoma: Reducing futile surgical exploration. PLoS ONE 2022;17:e0258522. [DOI: 10.1371/journal.pone.0258522] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Tzedakis S, Sindayigaya R, Dhote A, Marchese U, Barret M, Belle A, Coriat R, Barat M, Soyer P, Fuks D. Perihilar cholangiocarcinoma: What the radiologist needs to know. Diagnostic and Interventional Imaging 2022. [DOI: 10.1016/j.diii.2022.03.001] [Reference Citation Analysis]
5 Xu ZL, Ou YJ, Dai HS, Wan K, Bie P, Chen ZY, Zhang LD, Zhang CC. Elevated preoperative CA125 levels predicts poor prognosis of hilar cholangiocarcinoma receiving radical surgery. Clin Res Hepatol Gastroenterol 2021;45:101695. [PMID: 34147661 DOI: 10.1016/j.clinre.2021.101695] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
6 Mantripragada S, Chawla A. Cholangiocarcinoma: Part 1, Pathological and Morphological Subtypes, Spectrum of Imaging Appearances, Prognostic Factors and Staging. Curr Probl Diagn Radiol 2021:S0363-0188(21)00044-X. [PMID: 33827768 DOI: 10.1067/j.cpradiol.2021.03.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Lee T, Teng TZJ, Shelat VG. Carbohydrate antigen 19-9 — tumor marker: Past, present, and future. World J Gastrointest Surg 2020; 12(12): 468-490 [PMID: 33437400 DOI: 10.4240/wjgs.v12.i12.468] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 53] [Article Influence: 17.7] [Reference Citation Analysis]
8 Agrawal S, Gupta A, Gupta S, Goyal B, Siddeek RAT, Rajput D, Chauhan U, Kishore S, Gupta M, Kant R. Role of carbohydrate antigen 19-9, carcinoembryonic antigen, and carbohydrate antigen 125 as the predictors of resectability and survival in the patients of Carcinoma Gall Bladder. J Carcinog 2020;19:4. [PMID: 33033460 DOI: 10.4103/jcar.JCar_10_20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Peng D, Lu J, Hu H, Li B, Ye X, Cheng N. Lymphocyte to Monocyte Ratio Predicts Resectability and Early Recurrence of Bismuth-Corlette Type IV Hilar Cholangiocarcinoma. J Gastrointest Surg 2020;24:330-40. [PMID: 30671792 DOI: 10.1007/s11605-018-04086-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
10 Patkar S, Acharya MR, Kansaria R, Seth T, Shah A, Goel M. Cholangiocarcinoma Metastasizing to the Breast: An Unknown Entity. J Gastrointest Cancer 2020;51:654-7. [PMID: 31808056 DOI: 10.1007/s12029-019-00348-0] [Reference Citation Analysis]
11 Bird NTE, Manu N, Quinn L, Needham A, Jones R, Fenwick S, Poston G, Palmer D, Malik H. Evaluation of the utility of prognostic models for patients with resected hilar cholangiocarcinoma. HPB (Oxford) 2019;21:1376-84. [PMID: 31078423 DOI: 10.1016/j.hpb.2019.02.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Hu HJ, Jin YW, Shrestha A, Ma WJ, Wang JK, Liu F, Zhu YY, Zhou RX, Regmi P, Cheng NS, Li FY. Predictive factors of early recurrence after R0 resection of hilar cholangiocarcinoma: A single institution experience in China. Cancer Med 2019;8:1567-75. [PMID: 30868740 DOI: 10.1002/cam4.2052] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
13 Hu HJ, Jin YW, Zhou RX, Ma WJ, Yang Q, Wang JK, Liu F, Cheng NS, Li FY. Clinical Value of Inflammation-Based Prognostic Scores to Predict the Resectability of Hyperbilirubinemia Patients with Potentially Resectable Hilar Cholangiocarcinoma. J Gastrointest Surg 2019;23:510-7. [PMID: 30076591 DOI: 10.1007/s11605-018-3892-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
14 Fang T, Wang H, Wang Y, Lin X, Cui Y, Wang Z. Clinical Significance of Preoperative Serum CEA, CA125, and CA19-9 Levels in Predicting the Resectability of Cholangiocarcinoma. Dis Markers. 2019;2019:6016931. [PMID: 30863466 DOI: 10.1155/2019/6016931] [Cited by in Crossref: 16] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
15 Ma WJ, Wu ZR, Shrestha A, Yang Q, Hu HJ, Wang JK, Liu F, Zhou RX, Li QS, Li FY. Effectiveness of additional resection of the invasive cancer-positive proximal bile duct margin in cases of hilar cholangiocarcinoma. Hepatobiliary Surg Nutr 2018;7:251-69. [PMID: 30221153 DOI: 10.21037/hbsn.2018.03.14] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
16 Bird NTE, McKenna A, Dodd J, Poston G, Jones R, Malik H. Meta-analysis of prognostic factors for overall survival in patients with resected hilar cholangiocarcinoma. Br J Surg. 2018;105:1408-1416. [PMID: 29999515 DOI: 10.1002/bjs.10921] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 5.8] [Reference Citation Analysis]
17 Hu HJ, Jin YW, Zhou RX, Shrestha A, Ma WJ, Yang Q, Wang JK, Liu F, Cheng NS, Li FY. Hepatic Artery Resection for Bismuth Type III and IV Hilar Cholangiocarcinoma: Is Reconstruction Always Required? J Gastrointest Surg 2018;22:1204-12. [PMID: 29512002 DOI: 10.1007/s11605-018-3711-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
18 Wang JK, Hu HJ, Shrestha A, Ma WJ, Yang Q, Liu F, Cheng NS, Li FY. Can preoperative and postoperative CA19-9 levels predict survival and early recurrence in patients with resectable hilar cholangiocarcinoma? Oncotarget 2017;8:45335-44. [PMID: 28484084 DOI: 10.18632/oncotarget.17336] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
19 Qiu Y, He J, Chen X, Huang P, Hu K, Yan H. The diagnostic value of five serum tumor markers for patients with cholangiocarcinoma. Clin Chim Acta. 2018;480:186-192. [PMID: 29438681 DOI: 10.1016/j.cca.2018.02.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
20 Cravo M. Is CA 19-9 of Any Help in the Management of Cholangiocarcinoma? GE Port J Gastroenterol 2017;24:108-9. [PMID: 28848793 DOI: 10.1159/000457910] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]